415 Capital

Their model is a paradigm shift for the industry. Their incubator offers a centralized team and dedicated state-of-the-art facility creating a highly productive work environment with increased ideation, concept cross-pollination, concurrent work paths, faster decision-making and ultimately, superior products.

Distalmotion is a medical device company founded and based in Lausanne, Switzerland. Our mission is to remove the complexity out of robotic surgery in order to establish a new standard of care, where all patients in general surgery, gynecology and urology have access to best-in-class minimally invasive care. To do so, we have developed a surgical robot called Dexter. Designed, developed and manufactured in Switzerland, Dexter integrates the benefits of laparoscopy and robotics. Dexter combines the affordability of laparoscopy with the benefits of robotics through his novel, on-demand approach to robotic surgery. For further information, visit: dexter.surgery and follow us on LinkedIn and Twitter: @Distalmotion.

Aktiia was founded on a simple yet powerful insight: That continuous, convenient and accurate blood pressure monitoring (BPM) is key to tackling hypertension – the largest chronic condition in the world. Built on 20+ years of research, Aktiia's technology provides unparalleled innovation and ease in blood pressure data collection and machine learning modeling, offering personalized, continuous, and medical-grade blood pressure and heart rate data. Aktiia empowers people, researchers, and clinicians with unique blood pressure data paving the way for novel understanding and personalized patient care of hypertension. Aktiia’s mission has never been more critical, with over 1.4 billion people worldwide affected by high blood pressure, resulting in more than 18 million related deaths annually. The company is dedicated to changing the paradigm of blood pressure management, making it more accessible, accurate, and actionable for people worldwide.

Cardiac Success provides implant to improve cardiac function in patients with heart failure and/or functional mitral regurgitation.

CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.

Moray Medical develops a structural heart robotic delivery systems for edge-to-edge valve leaflet repair. Moray Medical is working to improve the quality of life for the millions suffering from leaky heart valves. Using our proprietary microfluidic robotics, more cardiologists can safely and cost-effectively treat the large number of patients who need mitral valve clip therapies.

R3 Vascular creates bioresorbable scaffold technology with a sirolimus coating for the treatment of peripheral arterial disease. R3 Vascular's polymer and proprietary technologies are used to create scaffolds that balance strength and flexibility for the treatment of peripheral arterial disease. The magnitude BRS device is the thinnest BRS ever tested in this clinical setting, with a strut thickness of 98 microns across its entire usable range of diameters.

Their model is a paradigm shift for the industry. Their incubator offers a centralized team and dedicated state-of-the-art facility creating a highly productive work environment with increased ideation, concept cross-pollination, concurrent work paths, faster decision-making and ultimately, superior products.